INTRODUCTION
============

Screening programs based on cytological staining techniques (Pap test) has led to a remarkable decline in incidence and mortality from invasive cervical cancer. However the Pap test efficacy is hampered by the high inter-observer variability and false negative/positive rates \[[@B1]\]. Even the \"gold standard\" histological assessment of cervical biopsies can be significantly affected by the intra- and inter-observer inconsistencies. Novel markers potentially applied on cytological/histological specimens could improve the identification of lesions with increased risk for progression. p16^INK4a^ (p16) is a tumor suppressor protein typically over-expressed in dysplastic and neoplastic cervix epithelium \[[@B1]\]. By means of a semi-quantitative analysis, several studies showed that high-grade lesions (cervical intraepithelial neoplasia \[CIN\] II to invasive cancer) exhibited a full-thickness and strong p16 immuno-staining \[[@B1]-[@B3]\]. However, a quantitative evaluation of p16 positive areas and cells in normal and affected cervical epithelium has not been performed.

The proliferative capacity of tumor cells is a fundamental feature of growing tumors. Ki-67 is a general proliferation marker \[[@B4]\] widely used to characterize malignant lesions including those of the cervix. The Ki-67 staining into the upper epithelium layers accomplishes the severity of cervical lesions \[[@B2],[@B5]\], but the exact nuclear function of Ki-67 antigen is largely unknown \[[@B4]\]. Thus, detecting markers directly involved in DNA replication might be a more precise way to evaluate proliferative behavior in dysplastic and neoplastic processes.

Minichromosome maintenance (MCM) proteins (2-7) complex consists of six subunits with essential functions in initiation and elongation of DNA replication \[[@B6]\]. Additionally, it has only been demonstrated in replicating cells \[[@B7]\].

MCM7 was reported to be associated with tumor formation, progression and malignant conversion \[[@B8]\]. It has also been considered a valuable proliferation marker in several cancer types, such as oral, prostatic, colonic \[[@B9]\], lung-adenocarcinoma and cervical \[[@B8]\]. Few studies investigated the MCM7 expression in human cervix tissues \[[@B7],[@B8]\], and there were no reports that comparatively evaluated the MCM7 expression with those originating from the most commonly used p16 and Ki-67 markers. The purpose of this study was to compare the potential of these three nuclear proteins as biomarkers for cervical disease progression.

MATERIALS AND METHODS
=====================

1. Tissue samples
-----------------

Twenty paraffin-embedded cervical samples (5 normal epithelium, 5 CIN I, 5 CIN II, and 5 CIN III cases) were obtained from the archive of a large histopathological diagnostic service laboratory. This study was approved by the National Council of Ethics in Research.

2. Indirect immuno-fluorescence
-------------------------------

Serial sections (5 µM-thick) were immersed in xylene, re-hydrated, heated in water-bath for 30 minutes for antigen retrieval, and blocked with 2% phosphate-buffered saline and bovine serum albumin (PBS/BSA) for 60 minutes at room temperature (RT). Sections were incubated overnight at 4℃ with the primary antibodies: p16 mouse-monoclonal antibody-clone JC8 (1:800, LabVision, Fremont, CA, USA), Ki-67 rabbit-polyclonal antibody-clone H-300 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MCM7 mouse-monoclonal antibody, clone DCS-141 (1:1000, Abcam, Cambridge, MA, USA). Sections were next incubated (1 hour-RT) with secondary antibodies: Cy2-Streptavidin-conjugated anti-mouse antibody (Molecular-Probes Inc., Eugene, OR, USA) and Cy5-conjugated anti-rabbit antibody (Molecular-Probes Inc.), washed, mounted (Hydramount, National Diagnostics, Atlanta, GA, USA) and examined at high-magnification fields (40x) by scanning confocal microscopy (Carl Zeiss LSM/510Meta, Carl Zeiss Jena, Germany).

Strong nuclear and cytoplasmic labeling was considered a p16 positive-reaction; the Ki-67/MCM7 markers\' positivity was based on strong nuclear labeling detection. Quantitative determination of p16 immuno-positive areas and the number of positive cells and/or nuclei for all markers was performed by the KS-300/Image Analyzer Carl Zeiss. Spearman\'s correlation statistical-technique was used for analyzing the association between the biomarker\'s expression and the cervical-epithelium histological grade. Pearson\'s correlation statistical-technique was used for comparative-evaluation between p16 positive cells/nuclei and Ki-67/MCM7 positive nuclei. A p\<0.05 was considered statistically significant. The quantitative results were also expressed in a semi-quantitative scale, by using previously published scoring-criteria \[[@B2]\]. The Ki-67 and MCM7 labeling indexes (LIs) were calculated by dividing the number of positive nuclei by the total nuclei number \[[@B9]\].

RESULTS
=======

Normal tissues did not show any positive areas or immuno-reactive cells for p16 ([Table 1](#T1){ref-type="table"}). However an increasing number of p16 immuno-labeled areas was observed along with the severity of cervical disease ([Table 1](#T1){ref-type="table"}). A similar result was verified when these values were expressed in a semi-quantitative scale: the majority of CIN I, II, and III samples exhibited a growing pattern of p16 positive areas ([Table 2](#T2){ref-type="table"}). In accordance with the quantitative p16 area analysis, an increase was observed in p16 positive cells according to the CIN severity degree ([Table 1](#T1){ref-type="table"}).

However, when these results were semi-quantitatively expressed the p16 immuno-labeling analysis within the CIN groups showed greater variability ([Table 2](#T2){ref-type="table"}). Regarding the Ki-67 results, the number of Ki-67 positive nuclei increased from normal to CIN II epithelium, but no notable differences were observed between CIN II and III values ([Table 1](#T1){ref-type="table"}). Most normal, CIN I and II tissue samples, showed a similar Ki-67 labeling pattern (+2 score), whereas the majority of CIN III samples scored as +3. A growing expression of MCM7 was observed from normal to CIN III samples, with the highest MCM7 expression values detected in CIN III cases ([Table 1](#T1){ref-type="table"}).

Accordingly, most of normal and all the CIN I samples were MCM7 scored as +2, while the majority (60%) of CIN II and III samples were scored as +3 and +4 ([Table 2](#T2){ref-type="table"}). The MCM7 LIs exhibited a good correlation with the Ki-67 LIs (p\<0.05), and the MCM7 labeling-index for each case was considerably higher than the corresponding Ki-67 LIs.

The obtained Ki-67 LIs mean values were 19.8 (with samples/values ranging from 15.8 to 22.5) for the normal epithelium, 27.31 (range, 8.4 to 33.75) for CIN I-group, 32.84 (range, 22.0 to 66.2) for CIN II-category, and 37.16 (range, 19.25 to 49.1) for CIN III-group (p\<0.05). The average MCM7 LIs values for the corresponding groups were 27.06 (with values ranging from 15.1 to 37.6), normal epithelium; 30.36 (range, 20.2 to 36.5), CIN I; 50.54 (range, 37.7 to 70.4), CIN II; and 67.26 (range, 39.0 to 100.0), CIN III; p\<0.05.

According to the biomarkers\' expression distribution through the cervical epithelium, all the normal cervical tissue samples were negative for p16 and showed Ki-67 and MCM7 labeling in the lower (1/3) basal epithelium ([Fig. 1](#F1){ref-type="fig"}). Forty percent of CIN I samples exhibited p16 immuno-expression in the basal layer, while 100% of CIN II and III samples showed labeling of 2/3 and 3/3 of the epithelium. Concerning the Ki-67 expression topology, 60% of CIN I and 100% of CIN II samples showed 2/3 of the epithelium staining while 60% of CIN III exhibited labeling in 3/3 of the epithelium. Most of the normal and CIN I tissue samples expressed MCM7 in the 1/3 basal-epithelium, whereas the majority of CIN II and III cases showed MCM labeling in 2/3 of the epithelium.

DISCUSSION
==========

In this study we have shown, using a quantitative-evaluation approach, that p16, Ki-67, and MCM7 markers are significantly correlated with cervical lesion progression. Several studies confirmed negative to minimal p16-staining in normal/reactive cervical biopsies, with considerable variability in the CIN grade samples presenting strong p16 immuno-reactivity \[[@B1],[@B3]\]. Therefore, quantitative analysis of p16 areas and/or cells seemed to be a better approach when performing the categorization of CIN groups than conventional semi-quantitative evaluation. Additionally, we performed a comparative analysis between Ki-67 and MCM7 proliferation-related proteins as CIN progression markers. Ki-67 positivity extending to 2/3 of the epithelium was reported to be associated with increasing cervical dysplasia degree \[[@B2],[@B5]\]. However, this marker specificity is low \[[@B2]\], Ki-67 expression-levels can be altered by external factors and there is no evidence that this protein is essential for cell proliferation \[[@B4]\]. Here, we observed a higher expression of both Ki-67 and MCM7 in high-grade when compared to low-grade lesions or normal cervical-epithelium. Few studies have examined MCMs as proliferation markers in cervical disease and have focused mostly in analyzing the MCM2/5 expression. In only one study the MCM7 staining topology-pattern was evaluated in cervical, normal and affected tissues \[[@B8]\]. Our results are concordant with this report, since a significant association between the p16, Ki-67, and MCM7 topology-patterns expression and human-cervical disease progression was observed. Other reports showed that MCM7 labeling-indexes were consistently higher than Ki-67 LIs in several cancer types \[[@B8],[@B9]\]. Previous studies have shown that, additionally to proliferative cells, MCM proteins were expressed in potent or early-proliferating cells \[[@B6]\]. Thus, these observations may imply that, Ki-67 does not label all proliferating cells of some tumors \[[@B4]\].

We believe that MCM7 offers a great advantage over other proliferating biomarkers, since it is not expressed in cells undergoing DNA repair \[[@B6]\] and exhibits a higher sensitivity to identify abnormal precursor cells than Ki-67/PCNA \[[@B8]\]. Consequently, MCM7 is regarded an excellent candidate marker for cancer screening, surveillance, and prognosis \[[@B7],[@B9]\]. In a prospective study involving the analysis of cervical smear samples from 455 Indian women, the combined use of MCM2/5-staining and Pap-counterstaining disclosed 10 previously missed cases of biopsy-proven cervical cancer or pre-cancer when using the standard Pap-staining \[[@B10]\]. Although this study was focused on the evaluation of MCM7 as an indicator of progressive-cervical disease in tissue samples, the biomarker expression demonstrated a satisfactory correlation with CIN progression, suggesting that MCM7 could be used as a valuable tool for improving the diagnosis and screening of pre-malignant lesions and cervical cancer.
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![Comparative immuno-fluorescent analysis of Ki-67, p16, and minichromosome maintenance 7 (MCM7) markers expression in human-cervical tissue-samples obtained by loop electrosurgical excision procedure (LEEP). The diagnoses were independently reviewed/confirmed by three certified pathologists. Positive Ki-67 and MCM7 cells show fluorescence-labeling confined to the nucleus (white), whereas p16-positive cells show nuclear/and/cytoplasmic labeling (green). Nuclei were immuno-labeled with propidium-iodide (red). CIN, cervical intraepithelial neoplasia.](jgo-23-11-g001){#F1}

###### 

Quantitative mean values of p16 immuno-expression area and the number of p16, Ki-67, and MCM7 positive cells/nuclei according to the histological diagnosis
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Values are presented as number (range).

MCM, minichromosome maintenance; CIN, cervical intraepithelial neoplasia.

^\*^p16 immuno-positive areas values were expressed in square micrometers (µm^2^).

###### 

Semi-quantitative values of p16 area and the p16, Ki-67, and MCM7 cells/nuclei immuno-labeling according to the histological diagnosis^\*^
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MCM, minichromosome maintenance; CIN, cervical intraepithelial neoplasia.

^\*^Percentage of samples from each histological diagnosis group exhibiting the considered marker expression. ^†^Samples were classified as 0, +1, +2, +3 according to the absence (0) or presence of 5-25%, 25-75%, and \>75% of p16 positive areas and cells. ^‡^Samples were scored as 0, +1, +2, +3, and +4 when exhibited none, 1-20%, 20-40%, 40-60%, and \>60% of Ki-67/MCM7 positive nuclei \[[@B2]\].
